HURA Stock Forecast & Price Target

TuHURA Biosciences is a phase 3 clinical stage company with a promising personalized cancer vaccine candidate that has the potential to overcome primary resistance to checkpoint inhibitors. This, combined with upcoming value inflection points and a recent stock decline, makes for an attractive entry point for investors. The company's Phase 1b/2a trial evaluating IFx-2.0 as adjunctive therapy with Keytruda shows potential to significantly increase its addressable patient population, while the Phase 2 and 3 trials evaluating TBS-2025 and IFx-2.0, respectively, also have promising interim and top-line results expected in the near future.

TuHURA Biosciences is a phase 3 clinical stage immuno-oncology company with a personalized cancer vaccine candidate that has shown potential in melanoma treatment, despite not being included in current revenue projections. With upcoming value inflection points, such as ASCO presentations and interim and top-line results from ongoing trials, and a recent stock decline, this presents an attractive entry point for investors. However, the recent financing has caused the analyst to lower their 12-month price target from $12 to $10 and maintain a current negative outlook on the stock.